Decera Clinical Education Oncology Podcast
Episodes
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting
28 Oct 2022
Contributed by Lukas
In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of H...
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
24 Oct 2022
Contributed by Lukas
In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2...
Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape
24 Oct 2022
Contributed by Lukas
In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a liv...
Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
04 Oct 2022
Contributed by Lukas
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer tr...
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
28 Sep 2022
Contributed by Lukas
In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022
30 Aug 2022
Contributed by Lukas
In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacifi...
Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management
22 Aug 2022
Contributed by Lukas
In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting...
HER2-Positive Breast Cancer: Current Approaches for Quality Care
28 Jul 2022
Contributed by Lukas
In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
21 Jul 2022
Contributed by Lukas
In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic ...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022
06 Jul 2022
Contributed by Lukas
In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating th...
Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
30 Jun 2022
Contributed by Lukas
In this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and ...
Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
19 May 2022
Contributed by Lukas
In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 ...
Call to Action and Reflection: Inclusive, Compassionate, and High-Quality Healthcare for Transgender Individuals
13 May 2022
Contributed by Lukas
In this episode for all healthcare professionals and any patient-facing clinical staff, Nelson F. Sanchez, MD, shares key insights on the need for equ...
Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience
02 May 2022
Contributed by Lukas
In this episode, Pharmacist Olivia Buckoski shares her experience undergoing medical and social transition and offers advice from the perspective of b...
Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials
15 Apr 2022
Contributed by Lukas
In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkp...
Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway
07 Apr 2022
Contributed by Lukas
In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoin...
Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer
06 Apr 2022
Contributed by Lukas
In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of p...
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL
31 Mar 2022
Contributed by Lukas
In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current bes...
Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma
21 Mar 2022
Contributed by Lukas
In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of p...
Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes
14 Mar 2022
Contributed by Lukas
In this podcast episode, Amy DeZern, MD, MHS, Daniel Pollyea, MD, MS, and Amer Zeidan, MBBS, discuss challenging cases in MDS, includingTreatment for ...
Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis
10 Mar 2022
Contributed by Lukas
In this episode, Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky discuss incorporating KIT-targeted therapi...
Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches
25 Feb 2022
Contributed by Lukas
In this episode, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphoma...
TKIs for Advanced HCC in the Second Line and Beyond
22 Feb 2022
Contributed by Lukas
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatm...
New Directions With PARP Inhibitors in Pancreatic Cancer
21 Feb 2022
Contributed by Lukas
In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitor therapy ...
Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples
18 Feb 2022
Contributed by Lukas
In this episode,Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss t...
Expert Insights on Advances in Immune Thrombocytopenia
07 Feb 2022
Contributed by Lukas
In this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc,provide expert insights on immune thrombocytopenia management, a...
Precision Medicine for aTTP: Expert Answers to Your Questions
01 Feb 2022
Contributed by Lukas
In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics...
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions
31 Jan 2022
Contributed by Lukas
In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topic...
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease
26 Jan 2022
Contributed by Lukas
In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I cli...
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management
14 Jan 2022
Contributed by Lukas
In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: Which patients should hav...
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations
10 Jan 2022
Contributed by Lukas
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nur...
Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations
10 Jan 2022
Contributed by Lukas
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses therapeutic options for younger, fit patients with AML and no targetable mu...
Strategies for Secondary AML and Emerging Therapies for AML
10 Jan 2022
Contributed by Lukas
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinica...
An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy
10 Jan 2022
Contributed by Lukas
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for int...
Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications
22 Dec 2021
Contributed by Lukas
In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R) myelodysplasti...
Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications
22 Dec 2021
Contributed by Lukas
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with ...
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
17 Dec 2021
Contributed by Lukas
In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-1...
The Evolving Role of TKIs in First-line Treatment of Advanced HCC
14 Dec 2021
Contributed by Lukas
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatme...
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
23 Nov 2021
Contributed by Lukas
In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, includin...
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
23 Nov 2021
Contributed by Lukas
In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving i...
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
09 Nov 2021
Contributed by Lukas
In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-g...
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma
02 Nov 2021
Contributed by Lukas
In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leve...
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
26 Oct 2021
Contributed by Lukas
In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecu...
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
21 Oct 2021
Contributed by Lukas
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line t...
First-Generation TRK Inhibitors: Clinical Evidence and Indications
15 Oct 2021
Contributed by Lukas
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first...
PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm
14 Oct 2021
Contributed by Lukas
In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the curr...
Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A
08 Oct 2021
Contributed by Lukas
In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available...
Rationale for NTRK Testing in Patients With Cancer
08 Oct 2021
Contributed by Lukas
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with vari...
Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer
07 Oct 2021
Contributed by Lukas
In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on ...
Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer
29 Sep 2021
Contributed by Lukas
In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 ...
Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma
28 Sep 2021
Contributed by Lukas
In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and...
Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
21 Sep 2021
Contributed by Lukas
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented f...
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs
24 Aug 2021
Contributed by Lukas
In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on h...
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
19 Aug 2021
Contributed by Lukas
In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4...
Essential Biomarker Testing in GI Cancers
18 Aug 2021
Contributed by Lukas
In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, ...
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions
05 Aug 2021
Contributed by Lukas
In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of heal...
The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer
30 Jul 2021
Contributed by Lukas
In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–ta...
Managing Serious Adverse Events Associated with BTK Inhibitor Treatment
27 Jul 2021
Contributed by Lukas
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. ...
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management
27 Jul 2021
Contributed by Lukas
In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. To...
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions
27 Jul 2021
Contributed by Lukas
In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Top...
BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications
23 Jul 2021
Contributed by Lukas
In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL...
Adverse Events Associated with BTK Inhibitor Treatment
23 Jul 2021
Contributed by Lukas
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics i...
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
20 Jul 2021
Contributed by Lukas
In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the t...
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies
19 Jul 2021
Contributed by Lukas
In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clin...
Expert Answers to HCP Questions on CAR T-Cell Therapy
19 Jul 2021
Contributed by Lukas
In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current bes...
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
16 Jul 2021
Contributed by Lukas
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, vene...
Caring for Patients With Newly Diagnosed Multiple Myeloma
14 Jul 2021
Contributed by Lukas
In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for ini...
Treatment Options for Patients With Multiple Myeloma After First Relapse
14 Jul 2021
Contributed by Lukas
In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on init...
Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions
12 Jul 2021
Contributed by Lukas
In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of health...
Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas
12 Jul 2021
Contributed by Lukas
In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 ...
Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer
30 Jun 2021
Contributed by Lukas
In this episode, Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professiona...
Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions
29 Jun 2021
Contributed by Lukas
In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrou...
Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
24 Jun 2021
Contributed by Lukas
In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 present...
Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions
17 Jun 2021
Contributed by Lukas
In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refrac...
Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer
19 May 2021
Contributed by Lukas
In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professional...
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
18 May 2021
Contributed by Lukas
In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding cli...
Immunotherapy for Advanced HCC: Case Series
17 May 2021
Contributed by Lukas
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other...
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany
13 May 2021
Contributed by Lukas
In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma inf...
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
04 May 2021
Contributed by Lukas
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment ...
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
28 Apr 2021
Contributed by Lukas
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients wi...
Expert Answers to Questions on Contemporary Management of Multiple Myeloma
22 Apr 2021
Contributed by Lukas
In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer a...
Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates
19 Apr 2021
Contributed by Lukas
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using P...
Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer
15 Apr 2021
Contributed by Lukas
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with oth...
Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer
06 Apr 2021
Contributed by Lukas
In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovar...
Expert Answers to Questions on PARP Inhibition for Prostate Cancer
06 Apr 2021
Contributed by Lukas
In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prost...
Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
26 Mar 2021
Contributed by Lukas
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, wit...
Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards
25 Mar 2021
Contributed by Lukas
In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer...
Targeting FGFR in Urothelial Cancer and Beyond
23 Mar 2021
Contributed by Lukas
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer...
Expert Answers to HCP Questions on Pancreatic Cancer Treatment
22 Mar 2021
Contributed by Lukas
In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best pract...
Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma
18 Mar 2021
Contributed by Lukas
In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell th...
Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer
17 Mar 2021
Contributed by Lukas
In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC ...
Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities
12 Mar 2021
Contributed by Lukas
In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy f...
Expert Insights on Highlights From ASH 2020 on Multiple Myeloma
12 Mar 2021
Contributed by Lukas
In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on t...
Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias
26 Feb 2021
Contributed by Lukas
In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chro...
Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer
24 Feb 2021
Contributed by Lukas
In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:Updated re...
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Argentina
22 Feb 2021
Contributed by Lukas
In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of ...
Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders
10 Feb 2021
Contributed by Lukas
In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on no...
Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms
05 Feb 2021
Contributed by Lukas
In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in M...
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Italy
04 Feb 2021
Contributed by Lukas
In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment o...
Expert Answers to Questions on Contemporary Management of Hemophilia A
04 Feb 2021
Contributed by Lukas
In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics...